These fusions have important clinical relevance—e.g., IGH::CRLF2 in Ph-like B-ALL, or DUX4 fusions associated with favorable prognosis—but require confirmation via high-resolution sequencing approaches such as high-depth WGS, RNA-seq, targeted PCR, or Sanger sequencing to map breakpoints accurately [29]. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.